ZYBERNO
Stock Report
Updated Jun 11, 2026

ZIVO BIOSCIENCE, INC. (ZIVOW)

Healthcare • Over The Counter

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
ZIVO BIOSCIENCE, INC. (ZIVOW) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-4,045.7%)
Return on Capital (Capital Efficiency):CRITICAL (-1,133.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ZIVO BIOSCIENCE, INC. (ZIVOW) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$383.23

Valuation Multiples (2)

P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$286.22K
B. Profitability Assessment

Return Metrics (4)

ROA:-801.1%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-4,045.7%
Net Margin Ttm:-4,059.7%
Ebitda Margin:-4,045.7%

TTM Performance (3)

Gross Margin Ttm:31.7%
Operating Margin Ttm:-4,045.7%
Net Margin Ttm:-4,059.7%

Yield Metrics (2)

Earnings Yield:-$500.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-687.5%
Latest Earnings Filed:2021-11-15

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.08x
Quick Ratio:0.08x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-427.18x
Times Interest Earned:-427.18

Capital Structure (4)

Working Capital:-3,332,869.00
Cash And Cash Equivalents:0.00
Long Term Debt:$220.12K
Net Debt:$285.84K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $209.03K
Linear Growth: 100.0%
📊 Click to view full ZIVOW Revenue analysis & methodology →
Cost Of Revenue Ttm:$142.82K

Profitability Breakdown (2)

Gross profit TTM: $66.21K
Linear Growth: 100.0%
📊 Click to view full ZIVOW Gross Profit analysis & methodology →
-$8.46M

Bottom Line Performance (3)

-$8.49M
Income Before Tax:$0.00
Ebitda Ttm:-8,456,422.00

Operating Expenses (5)

Operating Expenses:8,522,632.00
R And D Expense:3,695,819.00
Sga Expense:4,826,812.00
Income Tax Expense:$0.00
Interest Expense:31,279.00

Expense Ratios (3)

R And D To Revenue Percentage:5,631.7%
Sga To Revenue Percentage:7,355.1%
Ebitda Margin:-4,045.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$559.45K
Current Assets:$281.40K
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,846,055.00
Current Liabilities:3,614,268.00
Long Term Debt:$220.12K
Short Term Debt:$65.71K

Equity & Capital (3)

Equity:-$3.29M
Retained Earnings:-$143.85M
Common Stock:25,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:992,990.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:240,750.00
C. Cash Flow Analysis

Operating Activities (2)

-$4.04M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$404.99K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:245,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$34.39K
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (2)

EPS (Basic TTM):-0.50
Earnings Per Share Ttm:-$2.21

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$1.13

Book Value & Capital (2)

Book Value Per Share:-$0.86
Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.20x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:2,537.84
Cash Conversion Cycle:-4,535.84
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):100.0%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ZIVOW
Company Name:ZIVO BIOSCIENCE, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.83M
Shares Outstanding Basic:3.83M
Shares Outstanding Diluted:3.82M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-11 10:54:11 UTC
Data Timestamp:2026-06-11T10:54:11.923003
Scroll to Top